Hospital
Mercy Medical Center-Clinton, INC
Mercy Medical Center-Clinton, INC was paid $14.31M by Medicaid between Jan 2018 and Dec 2024, across 110 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoMERCY MEDICAL CENTER-CLINTON, INC
CLINTON, IA 52732
CLINTON, IA 52732
33aNPI1427093962assigned 06/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.31M
24GClaims248,125
24DCodes billed110
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Iowa
Rank by total paid#10 of 29
Median peer was paid$6.37M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 30,633 | $1.40M | |
| 2019 | 34,092 | $1.74M | |
| 2020 | 34,905 | $1.66M | |
| 2021 | 38,915 | $2.40M | |
| 2022 | 44,145 | $2.95M | |
| 2023 | 39,068 | $2.49M | |
| 2024incomplete | 26,367 | $1.68M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 22,084 | 20,605 | $3.72M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 19% | 32,565 | 26,379 | $2.66M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 10,538 | 9,707 | $2.30M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 5,558 | 4,944 | $1.63M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 8.3% | 9,248 | 8,526 | $1.19M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.2% | 11,932 | 11,250 | $1.03M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.8% | 3,840 | 3,710 | $398K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 5,497 | 4,974 | $229K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 3,793 | 3,471 | $198K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.4% | 670 | 649 | $196K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 1,307 | 508 | $158K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 666 | 631 | $122K |
98 more codes
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,684 | $78K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 685 | $68K |
| 20610 | <1% | 376 | $67K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 438 | $54K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 859 | $38K |
| 59025 | Fetal non-stress test | <1% | 240 | $35K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 57 | $22K |
| 11721 | <1% | 994 | $14K | |
| 87070 | <1% | 1,538 | $14K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 513 | $13K |
| 97597 | <1% | 157 | $11K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 323 | $10K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 18 | $7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 67 | $4K |
| 93017 | <1% | 66 | $4K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 55 | $4K |
| 73630 | <1% | 295 | $2K | |
| 80053 | Comprehensive metabolic panel | <1% | 18,714 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 180 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,980 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 25,557 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,425 | $2K |
| 80061 | Lipid panel | <1% | 124 | $1K |
| G0008 | Administration of influenza virus vaccine | <1% | 57 | $1K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,954 | $943.12 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,052 | $811.69 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 295 | $717.04 |
| 81001 | <1% | 6,609 | $649.44 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 42 | $619.50 |
| G0378 | Hospital observation service, per hour | <1% | 748 | $548.33 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 186 | $446.00 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 432 | $419.27 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 154 | $414.59 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 51 | $373.50 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14 | $336.08 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14 | $336.08 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,437 | $332.26 |
| 93242 | <1% | 14 | $322.81 | |
| 87631 | <1% | 695 | $303.93 | |
| 85027 | <1% | 1,195 | $288.11 | |
| Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | <1% | 39 | $277.11 |
| 97602 | <1% | 134 | $137.40 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 189 | $108.71 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 357 | $89.21 |
| 83690 | <1% | 4,730 | $76.47 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 624 | $68.24 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14 | $61.48 |
| 83735 | <1% | 4,429 | $56.47 | |
| 84484 | <1% | 4,834 | $55.67 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,227 | $44.91 |
| 81025 | <1% | 679 | $40.81 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,702 | $35.88 |
| 85610 | <1% | 2,891 | $34.90 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 852 | $30.11 |
| 85730 | <1% | 1,541 | $24.99 | |
| 83605 | <1% | 2,818 | $23.66 | |
| 81003 | <1% | 2,569 | $16.92 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 154 | $15.70 |
| 80076 | <1% | 528 | $15.68 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 361 | $13.44 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 681 | $13.16 |
| 85379 | <1% | 107 | $10.61 | |
| 84703 | <1% | 410 | $9.36 | |
| 84100 | <1% | 154 | $6.88 | |
| 83615 | <1% | 32 | $5.85 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 242 | $1.15 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 100 | $0.00 |
| 82803 | 0% | 80 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 411 | $0.00 |
| 82150 | 0% | 82 | $0.00 | |
| 82077 | 0% | 52 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 488 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 66 | $0.00 |
| 86141 | 0% | 268 | $0.00 | |
| 83880 | 0% | 520 | $0.00 | |
| 87040 | 0% | 97 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 195 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 258 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 121 | $0.00 |
| 73564 | 0% | 12 | $0.00 | |
| 86738 | 0% | 64 | $0.00 | |
| 87077 | 0% | 13 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 15 | $0.00 |
| 85651 | 0% | 38 | $0.00 | |
| 83520 | 0% | 38 | $0.00 | |
| 82553 | 0% | 28 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 17 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 461 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 771 | $0.00 |
| 85007 | 0% | 230 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 158 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 34 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 130 | $0.00 |
| 92504 | 0% | 12 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 17 | $0.00 |
| 80143 | 0% | 33 | $0.00 | |
| 87186 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOOD, MELLISSA (COO/CNO)
| Provider | Location | Paid |
|---|---|---|
| Mercy Specialty Clinic | Clinton, IA | $258K |
| Mercy Medical Center-Clinton, INC. | Clinton, IA | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.